Trientine - Merck/Tsumura/Valeant Pharmaceuticals

Drug Profile

Trientine - Merck/Tsumura/Valeant Pharmaceuticals

Alternative Names: Cuprid; Metalite; MK 681; Syprine; Tecza; Teta; TJA 250; Trien; Triestine

Latest Information Update: 07 Mar 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tsumura
  • Developer Merck & Co; Tsumura; Valeant Pharmaceuticals International
  • Class Ethylenediamines; Small molecules
  • Mechanism of Action Chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatolenticular degeneration

Most Recent Events

  • 03 Mar 2014 Valeant and Kadmon Pharmaceuticals agree to co-promote Syprine® in USA for Wilson's disease
  • 01 Jan 2011 Launched for Wilson's disease in Asia (PO)
  • 18 Dec 2000 Profile reviewed but no significant changes made
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top